Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

American racing champion and NASCAR Hall of Famer Darrell Waltrip has been diagnosed with Frontotemporal Dementia (FTD), his family has announced.

The 79-year-old former NASCAR driver and broadcaster will be stepping further away from public life following the diagnosis.

According to his family, Waltrip has FTD, which is being complicated by possible chronic traumatic encephalopathy (CTE), which they believe may be linked to injuries sustained during his racing career from 1972 to 2000.

“We wanted to share a health update with all of Darrell’s friends and fans who have supported him throughout his racing career. Recently, Darrell has been diagnosed with Frontotemporal Degeneration (FTD) complicated by possible Chronic Traumatic Encephalopathy (CTE) — likely from injuries incurred during his racing career,” the family said in a statement.

The family said Waltrip currently has only “minor noticeable symptoms” and is “happy and otherwise healthy,” spending time with his wife, Stevie, and their two daughters.

Why Can Repeated Head Injuries Raise CTE Concerns?

Chronic traumatic encephalopathy (CTE) is a progressive brain disease believed to be associated with repeated head injuries. It has most commonly been studied in contact-sport athletes and military personnel exposed to repeated head trauma.

Experts are still studying how the number and severity of head injuries contribute to CTE risk. Importantly, not everyone exposed to repeated head injuries develops CTE, and the condition can currently be definitively diagnosed only after death through examination of brain tissue.

A 2026 study led by researchers at Boston University and Harvard Medical School found that roughly one in four former NFL players who died between 2016 and 2021 had CTE.

CTE And Racing

Although CTE has historically received considerable attention in American football and other contact sports, repeated head impacts can occur in motorsports as well.

Waltrip is not alone. NASCAR Hall of Famer Fred Lorenzen was diagnosed with CTE by researchers after he died in 2024.

What Is Frontotemporal Degeneration?

Frontotemporal degeneration, also known as frontotemporal dementia (FTD), refers to a group of brain disorders that primarily affect the frontal and temporal lobes.

These areas are involved in personality, behavior, language, and other functions. Unlike Alzheimer's disease, memory loss may not be the first or most prominent symptom of FTD.

FTD can develop at a younger age than many other forms of dementia, sometimes affecting people in their 40s or 50s.

The condition can cause changes in:

• Personality and behavior
• Judgment and decision-making
• Emotional responses and empathy
• Speech and language
• Movement and coordination

What Are The Symptoms Of FTD?

Symptoms vary depending on which areas of the brain are most affected and generally worsen over time.

Behavioral Symptoms

• Personality and behavior changes
• Loss of empathy
• Poor judgment and impulsivity
• Socially inappropriate behavior
• Apathy or loss of interest
• Repetitive or compulsive behavior

• Difficulty finding words
• Trouble understanding speech or writing
• Difficulty naming objects
• Increasing difficulty speaking

• Tremors or stiffness
• Muscle weakness or spasms
• Poor balance and falls
• Difficulty swallowing
• Changes in speech or movement

Darrell Waltrip's Racing Legacy

Waltrip is one of NASCAR's most accomplished drivers, with 84 Cup Series victories and three Cup Series championships.

He won the Daytona 500 in 1989 and the Southern 500 in 1992. He also won the Coca-Cola 600 five times, making him the winningest driver in the race's history.

Waltrip later became a familiar voice in NASCAR broadcasting, working as a commentator for many years.

The UK NHS is set to review around 4,500 more breast cancer cases dating back to 2015 after a review found delayed diagnoses and 20 cases involving unnecessary breast removal surgery.

Hundreds of patients suffered harm under County Durham and Darlington NHS Foundation Trust in north-east England., according to the review.

The Trust has apologized and is using specialists from other hospitals to determine whether more women underwent unnecessary operations or received poor care.

"The trust will complete the reviews already under way covering care between January 2023 and February 2025. It will then look back one year at a time, starting with patients treated in 2022 and working backwards towards 2015," it said in a statement.

Review Could Cover 4,500 Cases

Also read: Alcohol-Linked Cancer Deaths Doubled In US: Colorectal Leads In Men, Breast Leads In Women

Board chair Alison Marshall apologized to women and families affected by the failings.

"I would like to offer a sincere apology to all the women and their families who have been affected by the failings in our breast services," she said, according to the BBC.

"I can't imagine the impact that has had."

She said the Trust could "not turn back the clock" but would be "open, honest and transparent" about the failings.

Chief nurse Gill Hunt said concerns were first raised in 2015 following a "service reconfiguration" and the loss of breast surgical trainee posts.

Till September 2, 2026, a total of 539 cases had been reviewed, and is expected to examine around 4,500 cases if it extends back to 2015.

The Trust said each year's findings will be "carefully considered" before it moves to the next earlier year. As per the report, the review could take five years, with women treated in 2015 potentially having their cases reviewed as late as 2031.

The admission came after the BBC reported last year that more than 200 patients were found to have suffered harm at the CDDFT.

"We have heard again today about the profound and lasting impact that failings in our breast services have had on women and their families," said Chief executive Steve Russell.

"We remain deeply sorry for the harm and distress caused, and for the times when, as a Trust, we should have listened more carefully, asked more questions and acted sooner," Russell added.

About 640 patients have contacted a special helpline seeking a review of their cases. The current review cost about £523,000 in its first year and involved nine reviewers examining around 80 cases a month.

20 Women Had Unnecessary Mastectomies

Read More: FDA Approves New Breast Cancer Treatment That Targets Resistance Before Cancer Progresses

About 514 cases reviewed by the trust so far, between January 2023 and February 2025, alongside the cases of 640 former patients who contacted a dedicated helpline.

Of the 514 cases, 315 patients have been found to have suffered harm, including 77 who were significantly harmed. One patient is known to have died.

The Trust was found to have a high number of mastectomies compared with other NHS trusts, with operations carried out "too quickly".

Breast Cancer Burden In UK

Breast cancer is the most common cancer in the UK, accounting for roughly 15% of all new cancer cases.

Around 60,763 new cases are diagnosed each year, according to Breast Cancer UK. An estimated 14,000-15,000 mastectomies are performed annually in the UK.

What Is A Mastectomy?

A mastectomy is surgery to remove the whole breast. Depending on the cancer, nearby lymph nodes and surrounding tissue may also be removed. It may be performed on one or both breasts depending on the type of cancer and individual risk factors.

Some patients may undergo breast reconstruction after a mastectomy to restore breast shape and symmetry.

The Food Safety and Standards Authority of India (FSSAI) has proposed restricting the manufacture and sale of analogue dairy products as “paneer.”

The draft Food Safety and Standards (Prohibition and Restrictions on Sales) Amendment Regulations, 2026, seeks to amend the 2011 regulations to specifically include “paneer made of constituents not derived from milk” among products whose sale would be restricted.

The move aims to prevent consumers from being misled about the nature and composition of such products and comes amid concerns over spurious dairy products.

What Does The Proposed Rule Say?

The proposed amendment seeks to insert a new clause under Regulation 2.1.1 of the existing regulations covering “paneer made of constituents not derived from milk.”

Products made using paneer or cheese analogues would therefore have to be clearly identified to consumers.

“Products already licensed or registered under the ‘Analogue in Dairy Context’ category would be required to discontinue the use of the term ‘Paneer’ in their nomenclature, labelling or marketing,” FSSAI said.

“The proposed amendment is aimed at ensuring that the nomenclature and presentation of food products accurately reflect their nature and composition, thereby enabling consumers to make informed choices,” the food regulator added.

Also read: Indian President Urges Celebrities to Stop Endorsing Health-Harming Products: Why It Matters

Since this is a draft regulation, FSSAI has invited objections and suggestions from stakeholders and members of the public.

The draft will be considered after 60 days, and the submissions received during this period will be considered before the proposed amendment is finalised.

Who Will Be Affected?

The proposed amendment would affect food business operators, including hotels, restaurants and catering services, that use substitutes for traditional dairy-based paneer or cheese products.

FSSAI said businesses using such products would need to prominently disclose this information at consumer touchpoints, including menu cards and packaging labels, in accordance with the Food Safety and Standards (Labelling and Display) Regulations.

In August, Maharashtra and Chhattisgarh banned the manufacture and sale of non-dairy paneer, commonly referred to as analogue paneer or analogue cottage cheese.

Dairy Paneer Vs Analogue Paneer

Traditional paneer is a fresh, soft, non-melting cheese commonly used in Indian cuisine. It is made by curdling milk with acidic ingredients such as lemon juice, vinegar or citric acid, followed by separation of the curds from the whey. The curds are then drained and pressed to remove excess water.

Analogue paneer, on the other hand, is made using non-dairy ingredients such as vegetable fats or oils and starches instead of milk fat.

Under FSSAI regulations:

• Paneer must be made from milk.
• Products containing non-dairy ingredients cannot be presented as conventional paneer.
• Analogue products must be appropriately identified so consumers are aware of their nature and composition.

Read More: FSSAI Tightens Food Warning Labels: Even One High Fat, Salt Or Sugar Ingredient Could Trigger A Red Warning

How Can Consumers Check The Product?

Consumers can start by checking the product label and menu description.

• Read the label: Look for terms such as “analogue” or “imitation” where applicable.
• Check the ingredients: Look for non-dairy fats, vegetable oils, starches or other substitutes.
• Check the product description: At restaurants and other food-service establishments, consumers can ask whether the paneer being served is dairy-based or an analogue product.

Home tests sometimes promoted online, including iodine or toor dal tests, should not be treated as definitive methods for identifying adulterated paneer. Laboratory testing is required to establish the composition of a food product reliably.